✦ LIBER ✦

A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung cancer

✍ Scribed by Giovanni B. Ratto; Paolo Zino; Sandro Mirabelli; Paolo Minuti; Riccardo Aquilina; Giovanni Fantino; Elisabetta Spessa; Marco Ponte; Paolo Bruzzi; Giovanni Melioli

Publisher: John Wiley and Sons
Year: 1996
Tongue: English
Weight: 750 KB
Volume: 78
Category: Article
ISSN: 0008-543X
DOI: 10.1002/(sici)1097-0142(19960715)78:2<244::aid-cncr9>3.0.co;2-l

No coin nor oath required. For personal study only.

✦ Synopsis

A previous pilot study from our group suggested that: (1) adoptive immunotherapy (AI) with tumor-infiltrating lymphocytes (TIL) and recombinant interleukin-2 (rIL-2) may be applied with safety to more than 80% of the patients who had surgery for Stage 111 nonsmall cell lung carcinoma (NSCLC); and (2) A1 could be useful in patients with locally advanced disease. The present randomized study was planned to assess the efficacy of A1 in the postoperative treatment of Stage 11, IIIa, or IIIb NSCLC.

📜 SIMILAR VOLUMES

Weekly docetaxel versus docetaxel/gemcit

Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer : A randomized phase 3 trial of the Minnie Pearl Cancer Research Network

✍ John D. Hainsworth; David R. Spigel; Cindy Farley; Dianna L. Shipley; James D. B 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB 👁 1 views

## Abstract ## BACKGROUND. The aim of this study was to compare the efficacy of single‐agent weekly docetaxel with the combination of docetaxel and gemcitabine in elderly and/or poor performance status patients with advanced nonsmall cell lung cancer (NSCLC). ## METHODS. Previously untreated pat